Silence Therapeutics plc Stock News

Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price in

Biotech stocks can offer some of the most explosive, exciting opportunities on the market. That is, if you find the right one.

Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.

Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript

Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest

Topline 36-week data from the phase 2 ALPACAR-360 study using its drug zerlasiran for patients with high lipoprotein[a] and stable atherosclerotic cardiovascular disease, expected in Q1 2024. There ar

Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest

Silence Therapeutics PLC Sponsored ADR (SLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

If you are looking for stocks that are well positioned to maintain their recent uptrend, Silence Therapeutics PLC Sponsored ADR (SLN) could be a great choice. It is one of the several stocks that pass

Silence Therapeutics PLC Sponsored ADR (SLN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many sto

SLN has fallen 65% after my last article. They produced good early data, they have decent cash, and there's no negative news. I can identify no reason for the stock to have declined so much.

ARCB, MRVL and SLN have been added to the Zacks Rank #5 (Strong Sell) List on May 9, 2023.

Silence Therapeutics plc (NASDAQ:SLN ) Q4 2022 Earnings Conference Call March 15, 2023 8:00 AM ET Company Participants Gem Hopkins - Head of Investor Relations & Corporate Communications Craig Tooman

Silence Therapeutics is an underfollowed British siRNA company focusing on cardiovascular and autoimmune diseases. Silence Therapeutics is a de-risked investment opportunity with significant potential

Silence Therapeutics PLC Sponsored ADR (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue movin